|Bid||110.15 x 0|
|Ask||112.25 x 0|
|Day's Range||110.20 - 111.60|
|52 Week Range||101.75 - 144.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Horseshoe crabs' icy-blue blood is set to remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to put on an equal footing a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
Today we'll look at bioMérieux S.A. (EPA:BIM) and reflect on its potential as an investment. Specifically, we're going...
Biomérieux, a French healthcare company specialising in diagnostics, said on Monday it had won more positive feedback from the U.S. Food & Drug Administration (FDA) regulator for its product aimed at helping test for the coronavirus. BioMerieux said its 'BIOFIRE® RP2.1' panel testing product, which includes 22 pathogens that cause respiratory infections including SARS-CoV-2 which causes the COVID-19 coronavirus, had won 'emergency use authorisation' from the FDA.